A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover

被引：0
|
作者：
Cupissol, Didier
Seiwert, Tanguy Y.
Fayette, Jerome
Ehrnrooth, Eva
Blackman, Alice Sarah
Cong, Xiuyu Julie
Cohen, Ezra E. W.
机构：
[1] Ctr Val dAurelle, Montpellier, France
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Boehringer Ingelheim GmbH & Co KG, Copenhagen, Denmark
[5] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6001
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC
    Colevas, A. Dimitrios Dimitrios
    Dinis, Jose Prime
    Chin, Venessa T.
    Costa, Diogo Alpuim
    Park, John J.
    Fang, Bruno
    Phan, Minh Duc
    Zhang, Yiran
    U'Ren, Lance
    Odegard, Jared
    Curtis, Kelly Kevelin
    Pirtle, Erika
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
    Rischin, Danny
    Boyer, Michael J.
    Brzezniak, Christina E.
    Colevas, A. Dimitrios
    Doebele, Robert Charles
    Gilbert, Jill
    Gitlitz, Barbara
    Khan, Saad A.
    Mehra, Ranee
    Seiwert, Tanguy Y.
    Kroll, Stew
    Pearce, Tillman E.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)
    Saba, N.
    Youssoufian, H.
    Cohen, E.
    Singh, J.
    Makris, L.
    Perdomini, M.
    MacIntyre, S.
    Denker, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S592 - S592
  • [34] Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
    Sacco, Assuntina G.
    Chen, Ruifeng
    Worden, Francis P.
    Wong, Deborah J. L.
    Adkins, Douglas
    Swiecicki, Paul
    Chai-Ho, Wanxing
    Oppelt, Peter
    Ghosh, Debanjali
    Bykowski, Julie
    Molinolo, Alfredo
    Pittman, Emily
    Estrada, M. Valeria
    Gold, Kathryn
    Daniels, Gregory
    Lippman, Scott M.
    Natsuhara, Amanda
    Messer, Karen
    Cohen, Ezra E. W.
    LANCET ONCOLOGY, 2021, 22 (06): : 883 - 892
  • [35] Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    A. Ruzsa
    M. Sen
    M. Evans
    L. W. Lee
    K. Hideghety
    S. Rottey
    P. Klimak
    P. Holeckova
    J. Fayette
    T. Csoszi
    J. Erfan
    U. Forssmann
    T. Goddemeier
    A. Bexon
    C. Nutting
    Investigational New Drugs, 2014, 32 : 1278 - 1284
  • [36] Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-na⟨ve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Ruzsa, A.
    Sen, M.
    Evans, M.
    Lee, L. W.
    Hideghety, K.
    Rottey, S.
    Klimak, P.
    Holeckova, P.
    Fayette, J.
    Csoszi, T.
    Erfan, J.
    Forssmann, U.
    Goddemeier, T.
    Bexon, A.
    Nutting, C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1278 - 1284
  • [37] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study
    Gui, Lin
    Chen, Xinrui
    Xie, Zucheng
    He, Xiaohui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
    Kim, E. S.
    Kies, M. S.
    Glisson, B. S.
    Ginsberg, L. E.
    Holsinger, F. C.
    Burke, B. J.
    Truong, M.
    Tsao, A. S.
    Hong, W. K.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [39] Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Fury, Matthew G.
    Baxi, Shrujal
    Shen, Ronglai
    Kelly, Katherine W.
    Lipson, Brynna L.
    Carlson, Diane
    Stambuk, Hilda
    Haque, Sofia
    Pfister, David G.
    ANTICANCER RESEARCH, 2011, 31 (01) : 249 - 253
  • [40] Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study
    Muratori, L.
    Texier, M.
    Mayache-Badis, L.
    Bidault, F.
    Iacob, M.
    Daste, A.
    Fayette, J.
    Lefebvre, G.
    Saada-Bouzid, E.
    Zanetta, S.
    Toullec, C.
    Cupissol, D.
    Salas, S.
    Kaminsky-Forrett, M-C.
    Johnson, A. C.
    Ferrand, F. R.
    Auperin, A.
    Guigay, J.
    Raynard, B.
    Even, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S809 - S810
12345